Abstract
Health-related quality of life (HRQoL) is a research priority in chronic diseases. We undertook a systematic review (registration #CRD42015024939) to identify, appraise and synthesize the evidence relating to HRQoL in idiopathic inflammatory myopathies (IIM). A comprehensive search was conducted in August 2015 using CINAHL, EMBase and Pubmed to identify studies reporting original data on HRQoL in IIM using generic HRQoL instruments. Characteristics of samples and results from selected studies were extracted and appraised using a standardized approach. Qualitative synthesis of the results was performed. Ten studies including a total of 654 IIM subjects were included in this systematic review. HRQoL was significantly impaired in all subsets of IIM compared with the general population. Disease activity, disease damage and chronic disease course were associated with poorer HRQoL. Insufficient or conflicting results were found in associations between clinical features, treatment, disease duration and mood or illness perception, and HRQoL in IIM. This study suggests that HRQoL is impaired in IIM. However, due to the paucity and heterogeneity of the evidence to date, robust estimates are lacking and significant knowledge gaps persist. There is a need for studies that systematically investigate the correlates and trajectory of HRQoL in IIM.
Highlights
Patient-reported outcomes (PROs), including health-related quality of life (HRQoL), are important outcomes in chronic diseases
The widely used Bohan & Peter classification criteria divide adult Idiopathic inflammatory myopathy (IIM) as follows: dermatomyositis (DM), polymyositis (PM), DM or PM associated with neoplasia and DM or PM associated with connective tissue diseases [2, 3]
All participants were over 18 years of age and had one of the following diagnoses: dermatomyositis (DM), polymyositis (PM), amyopathic dermatomyositis, hypomyopathic dermatomyositis, cancer-associated myositis, connective tissue disease-associated myositis ( known as overlap myopathy (OM)) or inclusion body myositis (IBM)
Summary
Patient-reported outcomes (PROs), including health-related quality of life (HRQoL), are important outcomes in chronic diseases. Idiopathic inflammatory myopathy (IIM) are a group of chronic autoimmune diseases characterized by muscle inflammation and weakness [1]. The widely used Bohan & Peter classification criteria divide adult IIM as follows: dermatomyositis (DM), polymyositis (PM), DM or PM associated with neoplasia and DM or PM associated with connective tissue diseases [2, 3]. A more recent classification adopted at the European Neuromuscular Centre Workshop (ENMC) in 2003 is increasingly used and introduced two new entities: necrotizing autoimmune myopathy (NAM) and nonspecific [5]. Inclusion body myositis (IBM), considered an IIM, has specific clinicopathologic features and separate classification criteria [6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
